Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Amgen (AMGN – Research Report) today. The company’s shares closed ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...

Regeneron Pharmaceuticals REGN underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of ...

Operator? Operator: Thank you. [Operator Instructions]. Our first question comes from Srikripa Devarakonda Truist Securities. Your line is open. Srikripa Devarakonda: Hey, guys. Thank you so much ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation ...

"ABBV's pain is BMY's gain," Truist Securities analyst Srikripa Devarakonda said in a note released Tuesday. "We see this as a negative for AbbVie (ABBV, Buy) and a positive for Bristol (BMY ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...

On Nov. 5, Srikripa Devarakonda from Truist Financial maintained a “Buy” rating on Eli Lilly, with a price target of $1,029, which indicates a 23.7% upside from the current levels.

Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...

Actor Vijay Deverakonda had come to attend a cultural fest at a college in Mumbai on Friday when the mishap took place.